

# Immuno Series | Conference Schedule 2021

## Oncolytic Viruses Symposium

Virtual Symposium  
1-day Event

- 300+ attendees and 15+ presentations
- An intensive one-day meeting on the latest data and strategies impacting the development of oncolytic viruses
- From discovery and biomarker development through to clinical research and regulatory approval, our symposium will bring together leading companies for a day of discussion and knowledge-sharing

## Immuno Week: **ONLINE**

Virtual Congress & Exhibition  
4-day Event

- 800+ attendees & 60+ presentations
- Four days of the latest immuno-oncology content, with thematic focusses each day to drill down into the most important updates affecting the industry from novel therapeutic modalities to the latest immunoassays and preclinical models
- Further talks provide insights into novel biomarker tools & genomic technologies enabling precision immunotherapies.

## IMMUNO

US IN-PERSON 2021

In-Person US Event  
(supported digitally)  
2-day Event

- 300+ attendees & 40+ presentations
- Explore the latest developments in the fast-growing Immuno-Oncology field through the Advances in Immuno-Oncology US event, which brings together experts from global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions all focussed on the development of immuno-oncology therapies and tools
- Co-located with Biomarkers US: In-Person


## IMMUNO

UK IN-PERSON 2021



In-Person UK Event  
(supported digitally)  
2-day Event

- 500+ attendees & 60+ presentations
- A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools
- 2 events in one: Advances in Immuno-Oncology Congress; Autoimmunity & Immunotherapy Congress



# Oncolytic Viruses Symposium

25 May 2021 | BST (UTC+1)

- 1-day Event
- Virtual Symposium



An intensive one-day meeting on the latest data and strategies impacting the development of oncolytic viruses. From discovery and biomarker development through to clinical research and regulatory approval, our symposium will bring together leading companies for a day of discussion and knowledge-sharing.

## Agenda at a Glance

### Oncolytic Viruses Symposium

#### Morning Session: Engineering & Translational Strategies

- Mechanistic understanding of viruses and tumour biology
- Engineering and optimisation strategies
- Preclinical and translational sciences
- Targeting the tumour microenvironment
- Understanding markers in oncolytic viruses

#### Afternoon Session: Accelerating Oncolytic Virus Immunotherapy To The Clinic

- Clinical trial updates and challenges
- Combination virotherapy strategies
- Delivering oncolytic viruses into solid tumours
- Navigating the regulatory landscape

“ I found the symposium very useful and gave a very good background, examples, and new tools to be used for this protein degradation projects. I will look forward to attending more workshops in future.”

- ATTENDEE OF 'LEAD IDENTIFICATION AND PROFILING IN TARGETED PROTEIN DEGRADATION', FROM THE FRANCIS CRICK INSTITUTE

## Benefits to Attending



**Hear from and meet with the leading figures in the oncolytic virus field**, offering innovative case studies on the latest strategies from discovery through to the clinic



**Interact with fellow attendees and speakers** during the live Q&As, taking place at the end of each presentation and through our interactive panel discussion on 'Understanding markers in oncolytic viruses'



**Explore how companies are accelerating oncolytic viruses to the clinic.** Presentations consider the best strategies, including combination virotherapies, likely to succeed in the clinic and deliver maximum patient benefit



**Gain insights into how oncolytic viruses can trigger an immune response in the body against cancer**, with consideration of the mechanistics of viruses, tumour biology and the tumour microenvironment.

## How It Works

### Live or Pre-recorded Presentations

Our interactive Symposiums are delivered through the swapcard platform, giving you the flexibility to deliver your presentation either live or as a recording. Should you opt for a live presentation, our staff will arrange a test run-through with you to familiarise you with the platform, as well as check that all technical aspects of your setup work well with the platform.

### Post-presentation Q&A Session

Whether delivered live or pre-recorded, once your presentation has ended you will be asked to engage in a Q&A session. We will receive questions from the audience and read these out to you to respond to, allowing you to delve into more detail on your topic, and connect with your audience.

- 4-day Event
- Virtual Congress & Exhibition



Four days of the latest immuno-oncology content, with thematic focusses each day to drill down into the most important updates affecting the industry from novel therapeutic modalities to the latest immunoassays and preclinical models. Further talks provide insights into novel biomarker tools & genomic technologies enabling precision immunotherapies.

## Agenda at a Glance

### Immuno Week: Online

#### 06 July 2021: Novel Therapeutic Modalities

##### Stream 1: Discovery & Development: Cell Therapies

- Traditional cell therapies: T-cells and NK cells; Non-traditional cell therapies: TCRs
- Targeting solid tumours through cell therapies

##### Stream 2: Discovery & Development: Antibody Therapies

- Best in class therapeutic antibodies for immuno-oncology
- Bispecific antibody case studies

#### 07 July 2021: Biomarkers in Immunotherapy

##### Stream 1: Novel Biomarker Tools & Technologies

- Novel biomarkers in the Immuno-Oncology space
- Improving patient response through biomarker development

##### Stream 2: Enabling Precision Immunotherapies

- Genomic strategies for Immuno-Oncology, including liquid biopsies and CTCs
- Strategies for delivering personalised immunotherapy

#### 08 July 2021: Advanced Models & Immunoassays

##### Stream 1: Preclinical Modelling of Safety & Efficacy

- Translating animal models into human and clinically-relevant models, including 3D, in-vivo and in-vitro models
- Safety & Toxicity considerations

##### Stream 2: Assay Development & Translational Strategies

- Assay development, including pharmacodynamic assays
- Preclinical efficacy and assay development

#### 09 July 2021

##### Morning Theme: Macrophage Drug Development

- Novel targets and pathways beyond CD47 and CAR-macrophages, including macrophages within the tumour microenvironment
- Optimising novel macrophage-targeting therapies for safe and efficacious treatments

##### Afternoon Theme: Immunotherapy: A Clinician's Perspective

- Immunotherapies in the clinic - opportunities and challenges
- Workshop: COVID-19 and Cancer

## Who will be there?

**800+ VPs, Directors & Senior Managers** from leading life sciences companies and research institutions in the following fields and more:

- Immuno-Oncology
- Cancer Immunology
- Oncology Biomarkers
- Cancer Vaccines
- Antibody Development
- Cell & Gene Therapy
- Oncolytic Viruses
- Microbiome for Immuno-Oncology
- Cancer Genetics
- Translational Immunology
- Preclinical and Clinical Oncology
- Combination Therapy
- Precision Medicine
- Immune Biology
- Screening, Assay Development and Modelling
- Immunology Discovery
- Macrophage Drug Development

## Virtual Event: How It Works

**Oxford Global's Virtual Event platform has been designed and developed to offer an immersive conference experience, delivering all the benefits of a live in-person event at the touch of a button.**



Watch this short video for an overview of the capabilities and functionality of our event platform: Swapcard



### Live & OnDemand Presentations

The Programme Agenda is the central point for presentation access, listing all on-demand and 'live' presentations across the event.

Each presentation will be pre-recorded and tested prior to the event and will incorporate a presentation 'page'. Your content will then be accessible on-demand throughout the event and for up to 1-week post-event.

### 'On-site' Support and Q&As

The Event Producer will be available throughout to ensure you get the most from the event. Whether your presentation is delivered on-demand or as-live, we will need to be able to share your slides on the platform for attendees to view.

You will have the ability to engage in Live Q&A and/or will receive questions directly from anyone viewing the recording. You will also have access to the full Virtual Event to engage in informal networking and 1-2-1 meetings.

- **2-day Event**
- **In-person US Event**  
*(Supported Digitally)*



Explore the latest developments in the fast-growing Immuno-Oncology field through the Advances in Immuno-Oncology US event, which brings together experts from global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions all focussed on the development of immuno-oncology therapies and tools. The event is co-located with our Biomarkers US: In-Person 2021 providing an in-depth look at the latest biomarker and translational data across multiple therapeutic areas.

## Agenda at a Glance

### Immuno US: In-Person

#### DAY ONE - 21 October 2021

##### Discovery & Development: Cell Therapies & Antibody Approaches

- Traditional Cell Therapies - T-Cells and NK Cells
- Non-Conventional Cell Therapies - Macrophages and TCRs
- Latest antibody-based approaches, including bispecifics

##### Biomarkers in Immuno-Oncology

- Novel biomarkers in the Immuno-Oncology space
- Improving patient responses through biomarker development
- Diagnostic tools within I-O, including liquid biopsies for precise treatments

#### DAY TWO - 22 October 2021

##### Discovery & Development: Intratumoural Immunotherapies & Combination Strategies

- Oncolytic and non-oncology viruses and agonists
- Delivering intratumoural immunotherapies for solid tumours
- Rational of different combinations, including combination of IO agents as well as radiotherapy & chemotherapy

##### Translational & Preclinical Development

- Assay development, including pharmacodynamic assays
- Translating animal models into human and clinically-relevant models for screening therapies
- Safety & Toxicity considerations

## Who will be there?


**300+ VPs, Directors & Senior Managers** from leading life sciences companies and research institutions in the following fields and more:

- Immuno-Oncology
- Target Discovery
- Oncology Biomarkers
- Cancer Vaccines
- Strategic Partnering
- Cancer Genetics
- Cancer Vaccines
- Agonist Antibodies
- Clinical Oncology
- Clinical Trial Management
- Immunotherapy

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers:

- Clinical Development
- Strategic Partnerships
- Cell-based Assays
- Antibody Engineering
- Clinical Management
- Diagnostics Development
- Preclinical Discovery
- Cell Engineering
- Mouse Models
- In Vitro Screening

**Last year's delegates in numbers** (incl. delegates from the co-located Biomarkers US):



- **2-day Event**
- **In-person UK Event**  
*(Supported Digitally)*



A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools.

## Agenda at a Glance

### Immuno UK: In-Person

#### DAY ONE

##### Discovery & Development: Cell Therapies & Combination Therapies

- Traditional Cell Therapies - T-Cells and NK Cells
- Non-Conventional Cell Therapies - Macrophages and TCRs
- Rational of different combinations, including combination of IO agents as well as radiotherapy & chemotherapy

##### Biomarkers in Immuno-Oncology

- Novel biomarkers in the Immuno-Oncology space
- Improving patient responses through biomarker development
- Diagnostic tools within I-O, including liquid biopsies for precise treatments

##### Mechanisms & Novel Treatments In Autoimmunity

- Understanding mechanisms that regulate autoimmunity
- Targetting the innate immune system
- Developing novel treatments for autoimmune diseases: biologics, drugs and gene therapy

#### DAY TWO

##### Discovery & Development: Intratumoural Immunotherapies & Antibody Therapies

- Oncolytic and non-oncology viruses and agonists
- Delivering intratumoural immunotherapies for solid tumours
- Latest antibody-based approaches, including bispecifics

##### Translational & Preclinical Development

- Assay development, including pharmacodynamic assays
- Translating animal models into human and clinically-relevant models for screening therapies
- Safety & Toxicity considerations

##### Enabling Precision Immunotherapies: Biomarker Tools & Genomic Technologies

- Genomic strategies for immuno-oncology, including liquid biopsies and CTCs
- Strategies for delivering personalised immunotherapy and precise targeting of tumour cells

## Who will be there?

**500+ VPs, Directors & Senior Managers** from leading life sciences companies and research institutions in the following fields and more:

#### Advances in Immuno-Oncology

- Immuno-Oncology
- Cancer Immunology
- Oncology Biomarkers
- Cancer Vaccines
- Antibody Development
- Cell & Gene Therapy
- Oncolytic Viruses
- Microbiome for Immuno-Oncology
- Cancer Genetics
- Translational Immunology
- Preclinical and Clinical Oncology
- Combination Therapy
- Precision Medicine

#### Autoimmunity & Immunotherapy

- Immune Biology
- Immunotherapy
- Autoimmune Disease
- Immunology & Inflammation
- Immunology Discovery

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers:

- Target Identification & Validation
- Custom Antibodies
- Combination Screening Platforms
- Biomarker Service Platforms
- New Technologies
- Patient Selection & Stratification
- Diagnostics
- Personalised Medicine Services
- Sequencing
- Genomic Markers
- Single Cell Technologies
- Assay Development & Screening
- Models
- Tumour Microenvironment
- CROs
- Safety & Toxicity
- Data Management
- Cell Engineering

## Last year's delegates in numbers:



82% Pharma and Biotech  
18% Academic Institution



33% Manager / Principal or Senior Scientist  
24% Scientist or similar  
22% C-Level  
21% Director



50% UK  
37% Europe  
10% US  
3% Rest of World